RTC binds NRTIs

Stable Identifier
R-HSA-9697051
Type
Reaction [binding]
Species
Homo sapiens
Related Species
Human immunodeficiency virus 1
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Antiretroviral (ARV) therapy, comprising a backbone of two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) plus another ARV, has helped extend life expectancy in people living with HIV (Orkin et al. 2018). NRTIs work by inhibiting HIV reverse transcriptase (RT), preventing transcription of HIV RNA to DNA. Emtricitabine, a cytidine analogue (Feng et al. 2009, Al-Majed et al. 2020) and tenofovir, an acyclic nucleotide diester analogue of adenosine monophosphate (McConville et al. 2015, Ray et al. 2016) are compounds which inhibit RT causing chain termination and inhibition of viral protein synthesis.
Literature References
PubMed ID Title Journal Year
19439089 The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study

Miller, MD, Goodman, D, Myrick, F, Svarovskaia, ES, Borroto-Esoda, K, Feng, JY, White, KL, Ly, JK

Retrovirology 2009
26640223 Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

Hitchcock, MJ, Fordyce, MW, Ray, AS

Antiviral Res. 2016
24741339 Efficacy of Tenofovir 1% Vaginal Gel in Reducing the Risk of HIV-1 and HSV-2 Infection

Boyd, P, Major, I, McConville, C

Clin Med Insights Womens Health 2014
32164970 Emtricitabine

Bakheit, AHH, Abdelhameed, AS, Al-Kahtani, HM, Al-Qahtani, BM, Al-Majed, AA

Profiles Drug Subst Excip Relat Methodol 2020
Participants
Participates
Disease
Name Identifier Synonyms
Human immunodeficiency virus infectious disease DOID:526 HIV infection
Authored
Reviewed
Created
Cite Us!